Page last updated: 2024-11-02

pentoxifylline and Albuminuria

pentoxifylline has been researched along with Albuminuria in 18 studies

Albuminuria: The presence of albumin in the urine, an indicator of KIDNEY DISEASES.

Research Excerpts

ExcerptRelevanceReference
"To compare the efficacy of pentoxifylline and captopril on urinary albumin excretion (UAE) rate in non-hypertensive diabetic patients with microalbuminuria."9.11Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients--a randomized, equivalent trial. ( Guerrero-Romero, F; Rodríguez-Morán, M, 2005)
"To investigate the anti proteinuric effect of pentoxifylline in diabetic patients, we prospectively studied in 25 hypertensive type 2 diabetic patients with persistent microalbuminuria and normal renal function the impact of combining pentoxifylline with an angiotensin converting enzyme inhibitor, lisinopril, on urinary albumin excretion and compared the results with those obtained in a control group of 25 type 2 diabetic patients treated with lisinopril only."9.10Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. ( Harmankaya, O; Seber, S; Yilmaz, M, 2003)
"We searched bibliographic databases for trials involving pentoxifylline that reported proteinuria, glomerular filtration rate, or blood pressure."8.84The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. ( Akbari, A; Doucette, S; Fergusson, D; Knoll, G; McCormick, BB; Sydor, A, 2008)
"Pentoxifylline is a drug with hemorheological actions used in the management of microcirculatory abnormalities, such as those usually seen in diabetic patients."6.68Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. ( Amato, D; García-Bulnes, G; Guerrero-Romero, F; Paniagua-Sierra, JR; Rodríguez-Morán, M; Salas-Ramírez, M, 1995)
"Among the microvascular complications, diabetic nephropathy is the most frequent cause of end-stage renal disease."6.44Efficacy of pentoxifylline in the management of microalbuminuria in patients with diabetes. ( Guerrero-Romero, F; Rodríguez-Morán, M, 2008)
"To compare the efficacy of pentoxifylline and captopril on urinary albumin excretion (UAE) rate in non-hypertensive diabetic patients with microalbuminuria."5.11Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients--a randomized, equivalent trial. ( Guerrero-Romero, F; Rodríguez-Morán, M, 2005)
"To investigate the anti proteinuric effect of pentoxifylline in diabetic patients, we prospectively studied in 25 hypertensive type 2 diabetic patients with persistent microalbuminuria and normal renal function the impact of combining pentoxifylline with an angiotensin converting enzyme inhibitor, lisinopril, on urinary albumin excretion and compared the results with those obtained in a control group of 25 type 2 diabetic patients treated with lisinopril only."5.10Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. ( Harmankaya, O; Seber, S; Yilmaz, M, 2003)
"From the available evidence, pentoxifylline seems to offer some beneficial effects in renal function improvement and reduction in albuminuria and proteinuria, with no obvious serious adverse effects for patients with DKD."4.88Pentoxifylline for diabetic kidney disease. ( Li, J; Liu, GJ; Shan, D; Wu, HM; Yuan, QY; Zhou, RL, 2012)
"We searched bibliographic databases for trials involving pentoxifylline that reported proteinuria, glomerular filtration rate, or blood pressure."4.84The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. ( Akbari, A; Doucette, S; Fergusson, D; Knoll, G; McCormick, BB; Sydor, A, 2008)
" The aim of this study is to evaluate the direct effects of losartan and/or pentoxifylline on expression of renal DDAH-1 and its relation to oxidative stress in the setting of albuminuria."3.79Effects of losartan and pentoxifylline on renal dimethylarginine dimethylaminohydrolase-1 expression in proteinuric nephropathy. ( Ahn, JS; Cho, JH; Choi, JY; Hyun, SH; Kim, CD; Kim, YL; Oh, EJ; Oh, SH; Park, SH; Ryu, HM; Yoon, SH, 2013)
"Pentoxifylline treatment (400 mg/twice a day) or standard treatment."2.90Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial. ( Barbieri, D; Carbayo, J; de Jose, AP; de Morales, AM; Delgado, A; Goicoechea, M; Luño, J; Verdalles, U; Verde, E, 2019)
"Pentoxifylline is a drug with hemorheological actions used in the management of microcirculatory abnormalities, such as those usually seen in diabetic patients."2.68Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. ( Amato, D; García-Bulnes, G; Guerrero-Romero, F; Paniagua-Sierra, JR; Rodríguez-Morán, M; Salas-Ramírez, M, 1995)
"Many patients with intermittent claudication are encouraged to exercise."2.67Pharmacological reduction of the systemically damaging effects of local ischaemia. ( Gosling, P; Paterson, IS; Sanghera, K; Shearman, CP; Simms, MH; Smith, FC; Tsang, GM, 1994)
"Pentoxifylline (PTF) has anti-inflammatory properties, which may be beneficial for diabetic nephropathy (DN)."2.52Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis. ( Shen, Y; Sun, ZL; Tian, ML; Zha, Y, 2015)
"Among the microvascular complications, diabetic nephropathy is the most frequent cause of end-stage renal disease."2.44Efficacy of pentoxifylline in the management of microalbuminuria in patients with diabetes. ( Guerrero-Romero, F; Rodríguez-Morán, M, 2008)

Research

Studies (18)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's5 (27.78)18.2507
2000's6 (33.33)29.6817
2010's7 (38.89)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lin, YC1
Chang, YH1
Yang, SY1
Wu, KD1
Chu, TS1
Navarro-González, JF1
Sánchez-Niño, MD1
Donate-Correa, J1
Martín-Núñez, E1
Ferri, C1
Pérez-Delgado, N1
Górriz, JL1
Martínez-Castelao, A1
Ortiz, A1
Mora-Fernández, C1
de Morales, AM1
Goicoechea, M1
Verde, E1
Carbayo, J1
Barbieri, D1
Delgado, A1
Verdalles, U1
de Jose, AP1
Luño, J1
Park, SH1
Hyun, SH1
Ryu, HM1
Ahn, JS1
Oh, SH1
Oh, EJ1
Yoon, SH1
Choi, JY1
Cho, JH1
Kim, CD1
Kim, YL1
He, T1
Cooper, ME1
Tian, ML1
Shen, Y1
Sun, ZL1
Zha, Y1
Laczy, B1
Cseh, J1
Mohás, M1
Markó, L1
Tamaskó, M1
Koszegi, T1
Molnár, GA1
Wagner, Z1
Wagner, L1
Wittmann, I1
Shan, D1
Wu, HM1
Yuan, QY1
Li, J1
Zhou, RL1
Liu, GJ1
Harmankaya, O1
Seber, S1
Yilmaz, M1
Rodríguez-Morán, M3
Guerrero-Romero, F3
Navarro, JF2
Milena, FJ1
Mora, C2
León, C1
García, J1
McCormick, BB1
Sydor, A1
Akbari, A1
Fergusson, D1
Doucette, S1
Knoll, G1
Paniagua-Sierra, JR1
García-Bulnes, G1
Salas-Ramírez, M1
Amato, D1
Tsang, GM1
Sanghera, K1
Gosling, P1
Smith, FC1
Paterson, IS1
Simms, MH1
Shearman, CP1
Solerte, SB1
Fioravanti, M1
Cerutti, N1
Severgnini, S1
Locatelli, M1
Pezza, N1
Rondanelli, M1
Trecate, L1
Balza, G1
Ferrari, E1
Gorson, DM1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of Calcitriol on Podocytes in Diabetic Kidney Disease Patients: Assessment of Urine Podocin, Urine Nephrin, Urine Interleukin-6, Urine KIM-1, Plasma Renin, and Albuminuria[NCT05298163]120 participants (Anticipated)Interventional2022-04-30Not yet recruiting
Interaction of Polymorphism rs35652124 With Curcumin Supplementation on NFE2L2 Gene Expression, Antioxidant Capacity and Renal Function in Patients With Early Diabetic Nephropathy[NCT03262363]Phase 2/Phase 3176 participants (Anticipated)Interventional2018-08-01Not yet recruiting
Phase 3 Study of the Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Renal Outcomes in Humans With Diabetic Kidney Disease[NCT01847313]Phase 320 participants (Actual)Interventional2013-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

MCP-1:Creatinine Ratio in Urine

Spot urine sample for MCP-1 and creatinine (NCT01847313)
Timeframe: Up to 26 weeks

Interventionng/mmol (Mean)
Liraglutide27.9
Control24.3

sCD163 in Serum

Serum sample for sCD163 (NCT01847313)
Timeframe: Up to 26 weeks

Interventionng/ml (Mean)
Liraglutide82
Control84

sCD163:Creatinine Ratio in Urine

Spot urine sample for MCP-1 and creatinine (NCT01847313)
Timeframe: Up to 26 weeks

Interventionpg/mmol (Mean)
Liraglutide27.9
Control24.3

Urinary Albumin Excretion Rate

Albuminuria as Measured by 24 Hour Albumin Excretion Rate (NCT01847313)
Timeframe: Up to 26 weeks

Interventionµg/min (Mean)
Liraglutide144.1
Control132.4

Reviews

5 reviews available for pentoxifylline and Albuminuria

ArticleYear
Update of pathophysiology and management of diabetic kidney disease.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2018, Volume: 117, Issue:8

    Topics: Albuminuria; Biomarkers; Diabetic Nephropathies; Disease Progression; Humans; Kidney Failure, Chroni

2018
Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis.
    International urology and nephrology, 2015, Volume: 47, Issue:5

    Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Press

2015
Pentoxifylline for diabetic kidney disease.
    The Cochrane database of systematic reviews, 2012, Feb-15, Issue:2

    Topics: Albuminuria; Anti-Inflammatory Agents, Non-Steroidal; Diabetic Nephropathies; Humans; Pentoxifylline

2012
Efficacy of pentoxifylline in the management of microalbuminuria in patients with diabetes.
    Current diabetes reviews, 2008, Volume: 4, Issue:1

    Topics: Albuminuria; Animals; Diabetic Angiopathies; Diabetic Nephropathies; Disease Models, Animal; Glomeru

2008
The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2008, Volume: 52, Issue:3

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Diabetic Nephropat

2008

Trials

7 trials available for pentoxifylline and Albuminuria

ArticleYear
Effects of Pentoxifylline on Soluble Klotho Concentrations and Renal Tubular Cell Expression in Diabetic Kidney Disease.
    Diabetes care, 2018, Volume: 41, Issue:8

    Topics: Adult; Aged; Albuminuria; Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Nephropathie

2018
Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial.
    Journal of nephrology, 2019, Volume: 32, Issue:4

    Topics: Aged; Aged, 80 and over; Albuminuria; Cardiovascular Diseases; Creatinine; Disease Progression; Foll

2019
Effects of pentoxifylline and pentosan polysulphate combination therapy on diabetic neuropathy in type 2 diabetes mellitus.
    Acta diabetologica, 2009, Volume: 46, Issue:2

    Topics: Albuminuria; Anticoagulants; Autonomic Nervous System; Blood Pressure; Body Mass Index; Creatinine;

2009
Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients.
    Renal failure, 2003, Volume: 25, Issue:3

    Topics: Aged; Albumins; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Blood Pressure; C

2003
Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients--a randomized, equivalent trial.
    Clinical nephrology, 2005, Volume: 64, Issue:2

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Captopril; Chi-Square Distribution; Diabetes

2005
Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients.
    Clinical nephrology, 1995, Volume: 43, Issue:2

    Topics: Adult; Albuminuria; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Do

1995
Pharmacological reduction of the systemically damaging effects of local ischaemia.
    European journal of vascular surgery, 1994, Volume: 8, Issue:2

    Topics: Aged; Albuminuria; Capillary Permeability; Double-Blind Method; Exercise Test; Exercise Tolerance; F

1994

Other Studies

6 other studies available for pentoxifylline and Albuminuria

ArticleYear
Effects of losartan and pentoxifylline on renal dimethylarginine dimethylaminohydrolase-1 expression in proteinuric nephropathy.
    American journal of nephrology, 2013, Volume: 37, Issue:5

    Topics: Acetylglucosaminidase; Albuminuria; Amidohydrolases; Angiotensin II Type 1 Receptor Blockers; Animal

2013
Diabetic nephropathy: renoprotective effects of pentoxifylline in the PREDIAN trial.
    Nature reviews. Nephrology, 2014, Volume: 10, Issue:10

    Topics: Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Free Radi

2014
Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration.
    American journal of nephrology, 2006, Volume: 26, Issue:6

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Cytokines; Diabetic Nephropathies; G

2006
Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration.
    American journal of nephrology, 2006, Volume: 26, Issue:6

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Cytokines; Diabetic Nephropathies; G

2006
Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration.
    American journal of nephrology, 2006, Volume: 26, Issue:6

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Cytokines; Diabetic Nephropathies; G

2006
Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration.
    American journal of nephrology, 2006, Volume: 26, Issue:6

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Cytokines; Diabetic Nephropathies; G

2006
Retrospective analysis of long-term hemorheologic effects of pentoxifylline in diabetic patients with angiopathic complications.
    Acta diabetologica, 1997, Volume: 34, Issue:2

    Topics: Adult; Aged; Albuminuria; Blood Pressure; Blood Viscosity; Diabetic Angiopathies; Female; Fibrinogen

1997
Reduction of macroalbuminuria with pentoxifylline in diabetic nephropathy. Report of three cases.
    Diabetes care, 1998, Volume: 21, Issue:12

    Topics: Aged; Aged, 80 and over; Albuminuria; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic

1998
Antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy.
    Diabetes care, 1999, Volume: 22, Issue:6

    Topics: Albuminuria; Diabetic Nephropathies; Humans; Pentoxifylline; Proteinuria; Tumor Necrosis Factor-alph

1999